Clonotyping for precision oncology.
Advances in identifying subpopulations of cancer cells and reconstructing the clonal evolution of tumors greatly enhance our understanding of the molecular events within a patient and their context relative to one another. In the rapidly unfolding era of personalized medicine, the ability to monitor clonal dynamics throughout patient care has significant clinical implications for the appropriate development or application of targeted therapies as well as understanding the potential mechanisms driving resistance. In this review, we discuss advances in biotechnology and bioinformatics that improve precision treatment by dissecting clonal evolution, focusing first on the initial discoveries in lymphomas and leukemias followed by the more recent applications to advance our understanding of prostate cancer (PCa).
McDonnell Genome Institute, Washington University School of Medicine, St Louis, MO 63110, USA; Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO 63110, USA.
Ha X
HX
Dang
McDonnell Genome Institute, Washington University School of Medicine, St Louis, MO 63110, USA; Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO 63110, USA; Alvin J. Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA; Department of Biomedical Engineering, Washington University School of Medicine, St Louis, MO 63110, USA. Electronic address: cmaher@dom.wustl.edu.
Christopher A
CA
Maher
D019295:Computational Biology / Q000379:methods; D006801:Humans; D008495:Medical Oncology / Q000379:methods; D058990:Molecular Targeted Therapy / Q000379:methods; D009369:Neoplasms / Q000188:drug therapy*; D057285:Precision Medicine / Q000379:methods